Dividends & Buybacks ·
CEO Alon Ben-Noon announced that NeuroSense Therapeutics is preparing to initiate its pivotal Phase 3 PARAGON study…
NRSNNeuroSense Therapeutics Ltd.
CEO Alon Ben-Noon announced that NeuroSense Therapeutics is preparing to initiate its pivotal Phase 3 PARAGON study for PrimeC in ALS, which will enroll approximately 300 participants. Securing financing has taken longer than anticipated; however, the CEO and CFO each invested $200,000 in April 2026 alongside a significant existing investor. The company is pursuing strategic partnerships and non-dilutive funding while preparing a New Drug Submission to Health Canada for December 2026 based on Phase 2b data. To address Nasdaq listing deficiencies regarding the minimum bid price, an upcoming shareholder meeting will include a proposal authorizing the Board to effect a reverse share split within a range of 1:4 to 1:40 if necessary. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing disease-modifying treatments for neurodegenerative diseases.